Antibiotic treatment of acute uncomplicated cystitis based on rapid urine test and local epidemiology: lessons from a primary care series

Manuel Etienne, Emmanuel Lefebvre, Noëlle Frebourg, Hélène Hamel, Martine Pestel-Caron, François Caron, Bacyst Study Group, Philippe André, Alain Barbot, Nicole Bénard, Danièle Bouillon, Pascal Boulet, Thomas Bourez, Laurence Brenet, Jean-Michel Bunel, Martine Courtier, François De Golmard, Marc Durand, Pierre Fainsilber, Rodolphe Hautot, Jean-Loup Hermil, Pascal Julienne, Marie-Catherine Lagaude, Karine Larese, Laurent Laval, Rrené Le, Janick Lefebvre, Laure Lefebvre, Serge Lejeal, Jérome Longueville, Jean-Pierre Mineo, Philippe Nguyen-than, Xavier Odoux, Marc-Henri Othman, Roseline Peluchon, Marc Salaun, Sébastien Taupin, Jean-Paul Thueux, Françoise Valla, Jean Van Elslande, Manuel Etienne, Emmanuel Lefebvre, Noëlle Frebourg, Hélène Hamel, Martine Pestel-Caron, François Caron, Bacyst Study Group, Philippe André, Alain Barbot, Nicole Bénard, Danièle Bouillon, Pascal Boulet, Thomas Bourez, Laurence Brenet, Jean-Michel Bunel, Martine Courtier, François De Golmard, Marc Durand, Pierre Fainsilber, Rodolphe Hautot, Jean-Loup Hermil, Pascal Julienne, Marie-Catherine Lagaude, Karine Larese, Laurent Laval, Rrené Le, Janick Lefebvre, Laure Lefebvre, Serge Lejeal, Jérome Longueville, Jean-Pierre Mineo, Philippe Nguyen-than, Xavier Odoux, Marc-Henri Othman, Roseline Peluchon, Marc Salaun, Sébastien Taupin, Jean-Paul Thueux, Françoise Valla, Jean Van Elslande

Abstract

Background: Acute uncomplicated cystitis (AUC) is an ideal target of optimization for antibiotic therapy in primary care. Because surveillance networks on urinary tract infections (UTI) mix complicated and uncomplicated UTI, reliable epidemiological data on AUC lack. Whether the antibiotic choice should be guided by a rapid urine test (RUT) for leukocytes and nitrites has not been extensively studied in daily practice. The aim of this primary care study was to investigate local epidemiology and RUT-daily use to determine the optimal strategy.

Methods: General practitioners included 18-65 years women with symptoms of AUC, performed a RUT and sent urines for analysis at a central laboratory. Different treatment strategies were simulated based on RUT and resistance results.

Results: Among 347 enrolled patients, 78% had a positive urine culture. Escherichia coli predominated (71%) with high rates of susceptibility to nitrofurantoin (100%), fosfomycin (99%), ofloxacin (97%), and even pivmecillinam (87%) and trimethoprim-sulfamethoxazole (87%). Modelization showed that the systematic use of RUT would reduce by 10% the number of patients treated. Fosfomycin for patients with positive RUT offered a 90% overall bacterial coverage, compared to 98% for nitrofurantoin. 95% for ofloxacin, 86% for trimethoprim-sulfamethoxazole and 78% for pivmecillinam.

Conclusion: Local epidemiology surveillance data not biased by complicated UTI demonstrates that the worldwide increase in antibiotic resistance has not affected AUC yet. Fosfomycin first line in all patients with positive RUT seems the best treatment strategy for AUC, combining good bacterial coverage with expected low toxicity and limited effect on fecal flora.

Trial registration: The current study was registered at clinicaltrials.gov (NCT00958295).

References

    1. AFSSAPS (Agence française de sécurité sanitaire des produits de santé) AFSSAPS Practice recommendations for diagnosis and antibiotic therapy of adult community urinary tract infections. Med Mal Infect. 2008;14:S203–S252.
    1. Scottish Intercollegiate Guidelines Network. Management of suspected bacterial urinary tract infection in adults: a national clinical guideline. 2012. pp. 1–52. Available at: .
    1. Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B, Jinenez Cruz F, Selvaggi FP. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU) EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU) Eur Urol. 2001;14(5):576–588. doi: 10.1159/000049840.
    1. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE. Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;14:e103–e120.
    1. Lopardo G, Fridman D, Gonzalez Arzac M, Calmaggi A, Smayevsky J, Podesta O, Clara L. Uropathogen resistance: are laboratory-generated data reliable enough? J Chemother. 2007;14:33–37. doi: 10.1179/joc.2007.19.1.33.
    1. Stamm WE, Counts GW, Running KR, Fihn S, Turck M, Holmes KK. Diagnosis of coliform infection in acutely dysuric women. N Engl J Med. 1982;14:463–468. doi: 10.1056/NEJM198208193070802.
    1. Société Française de Microbiologie. Rémic. Référentiel en Microbiologie Médicale Volume 1. 4. PARIS: Société Française de Microbiologie; 2012.
    1. McIsaac WJ, Moineddin R, Ross S. Validation of a Decision Aid to Assist Physicians in Reducing Unnecessary Antibiotic Drug Use for Acute Cystitis. Arch Intern Med. 2007;14:2201–2206. doi: 10.1001/archinte.167.20.2201.
    1. Hummers-Pradier E, Ohse AM, Koch M, Heizmann WR, Kochen MM. Management of urinary tract infections in female general practice patients. Fam Pract. 2005;14(1):71–77.
    1. McIsaac WJ, Low DE, Biringer A, Pimlott N, Evans M, Glazier R. The impact of empirical management of acute cystitis on unnecessary antibiotic use. Arch Intern Med. 2002;14:600–605. doi: 10.1001/archinte.162.5.600.
    1. Christiaens TCM, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract. 2002;14:729–734.
    1. Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA: The Journal of the American Medical Association. 2002;14:2701–2710. doi: 10.1001/jama.287.20.2701.
    1. Giesen LGM, Cousins G, Dimitrov BD, van de Laar FA, Fahey T. Predicting acute uncomplicated urinary tract infection in women: a systematic review of the diagnostic accuracy of symptoms and signs. BMC Fam Pract. 2010;14:78. doi: 10.1186/1471-2296-11-78.
    1. Foxman B, Barlow R, D’Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;14:509–515. doi: 10.1016/S1047-2797(00)00072-7.
    1. Little P, Turner S, Rumsby K, Jones R, Warner G, Moore M, Lowes JA, Smith H, Hawke C, Leydon G, Mullee M. Validating the prediction of lower urinary tract infection in primary care: sensitivity and specificity of urinary dipsticks and clinical scores in women. Br J Gen Pract. 2010;14:495–500. doi: 10.3399/bjgp10X514747.
    1. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;14:159–166. doi: 10.1016/S1473-3099(08)70041-0.
    1. Hansen DS, Schumacher H, Hansen F, Stegger M, Hertz FB, Schønning K, Justesen US, Frimodt-Møller N. Extended-spectrum β-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: Prevalence, β-lactamase distribution, phylogroups, and co-resistance. Scand J Infect Dis. 2012;14:174–181. doi: 10.3109/00365548.2011.632642.
    1. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JDD, Quentin C, Calbo ES, Azap OK, Arpin C, Pascual A, Livermore DM, Garau J, Carmeli Y. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;14:682–690. doi: 10.1086/604713.
    1. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruíz M, Peña C, Almela M, Almirante B, Grill F, Colomina J, Giménez M, Oliver A, Horcajada JP, Navarro G, Coloma A, Pascual A. Community-Onset Bacteremia Due to Extended-Spectrum β-Lactamase–Producing Escherichia coli:Risk Factors and Prognosis. Clin Infect Dis. 2010;14:40–48. doi: 10.1086/649537.
    1. Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, Domínguez-Gil González M, Gómez-Nieto A, Palacios-Martín T, González-Sagrado M, Dueñas-Laita A, Pérez-Castrillón JL. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract. 2012;14:891–896. doi: 10.1111/j.1742-1241.2012.02991.x.
    1. Aubin C. Does This Woman Have an Acute Uncomplicated Urinary Tract Infection? Ann Emerg Med. 2007;14:106–108. doi: 10.1016/j.annemergmed.2006.09.022.
    1. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med. 2012;14:1028–1037. doi: 10.1056/NEJMcp1104429.
    1. Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med. 2007;14:2207–2212. doi: 10.1001/archinte.167.20.2207.
    1. Société Française de Microbiologie`, editor. Société Française de Microbiologie. Recommandations 2011 du Comité de l'antibiogramme de la Société Française de Microbiologie. Paris; 2012.
    1. Falagas ME, Vouloumanou EK, Togias AG, Karadima M, Kapaskelis AM, Rafailidis PI, Athanasiou S. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;14:1862–1877. doi: 10.1093/jac/dkq237.
    1. Pitkäjärvi T, Pyykönen ML, Kannisto K, Piippo T, Viita P. Pivmecillinam treatment in acute cystitis. Three versus seven days study. Arzneimittelforschung. 1990;14:1156–1158.
    1. De Backer D, Christiaens T, Heytens S, De Sutter A, Stobberingh EE, Verschraegen G. Evolution of bacterial susceptibility pattern of Escherichia coli in uncomplicated urinary tract infections in a country with high antibiotic consumption: a comparison of two surveys with a 10 year interval. J Antimicrob Chemother. 2008;14:364–368. doi: 10.1093/jac/dkn197.
    1. Hovelius B, Mårdh PA, Nygaard-Pedersen L, Wathne B. Nalidixic acid and pivmecillinam for treatment of acute lower urinary tract infections. Scand J Prim Health Care. 1985;14:227–232. doi: 10.3109/02813438509013954.
    1. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009;14:407–413. doi: 10.1016/j.ijantimicag.2009.04.012.
    1. Nicolle LE. Pivmecillinam for the treatment of acute uncomplicated urinary infection. Int J Clin Pract. 1999;14:612–617.
    1. Neuzillet Y, Naber KG, Schito G, Gualco L, Botto H. French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy. Med Mal Infect. 2012;14:66–75. doi: 10.1016/j.medmal.2011.07.005.
    1. Sabuncu E, David J, Bernède-Bauduin C, Pépin S, Leroy M, Boëlle P-Y, Watier L, Guillemot D. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002–2007. PLoS Med. 2009;14:e1000084. doi: 10.1371/journal.pmed.1000084.
    1. Holmberg L, Boman G, Böttiger LE, Eriksson B, Spross R, Wessling A. Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med. 1980;14:733–738. doi: 10.1016/0002-9343(80)90443-X.
    1. Linhares IS, Raposo T, Rodrigues AN, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000–2009) BMC Infect Dis. 2013;14:1–1. doi: 10.1186/1471-2334-13-1.
    1. Fabre R, Mérens A, Lefebvre F, Epifanoff G, Cerutti F, Pupin H, Tardif D, Cavallo JD, Ternois I. Susceptibility to antibiotics of Escherichia coli isolated from community-acquired urinary tract infections. Med Mal Infect. 2010;14:555–559. doi: 10.1016/j.medmal.2010.03.002.
    1. Vellinga A, Tansey S, Hanahoe B, Bennett K, Murphy AW, Cormican M. Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model. J Antimicrob Chemother. 2012;14:2523–2530. doi: 10.1093/jac/dks222.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren